Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody

Biochem Biophys Res Commun. 2021 Mar 19:545:33-39. doi: 10.1016/j.bbrc.2021.01.075. Epub 2021 Jan 31.

Abstract

Zika virus (ZIKV) infection in both infants and adults is associated with neurological complications including, but not limited to, microcephaly and Guillain-Barre syndrome. Antibody therapy can be effective against virus infection. We isolated ZIKV envelope domain III-specific neutralizing antibodies (nAbs) from two convalescent patients with ZIKV infection. One antibody, 2F-8, exhibited potent in vitro neutralizing activity against Asian and American strains of ZIKV. To prevent FcγR-mediated antibody-dependent enhancement, we prepared IgG1 with LALA variation. A single dose of 2F-8 in the context of IgG1 or IgG1-LALA prior to or post lethal ZIKV challenge conferred complete protection in mice.

Keywords: Antibody-dependent enhancement; Guillain-Barre syndrome; Microcephaly; Neutralizing antibody; Zika virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Neutralizing / administration & dosage
  • Antibodies, Neutralizing / immunology*
  • Antibodies, Viral / administration & dosage
  • Antibodies, Viral / immunology*
  • Antibody Specificity
  • Disease Models, Animal
  • Female
  • Humans
  • In Vitro Techniques
  • Mice
  • Mice, 129 Strain
  • Mice, Knockout
  • Neutralization Tests
  • Pregnancy
  • Protein Domains
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / immunology
  • Viral Envelope Proteins / chemistry
  • Viral Envelope Proteins / immunology*
  • Zika Virus / chemistry
  • Zika Virus / immunology*
  • Zika Virus Infection / immunology
  • Zika Virus Infection / prevention & control

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Recombinant Proteins
  • Viral Envelope Proteins